RxDoctor Payments Data

Deborah Boland, DO

Neurology · Pensacola, FLNPI 1093976680

Payments from drug & device makers

$18,799in general payments, 2019–2025

Across 250 payments — averaging $75.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Sunovion Pharmaceuticals Inc.$2K
  • Acorda Therapeutics, Inc$2K
  • Amneal Pharmaceuticals LLC$496
  • Medtronic$396
  • Boston Scientific$367
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$2,80515%
  • Speaking & faculty fees$8,48345%
  • Travel & lodging$2261%
  • Food & beverage$7,11338%
  • Education$1721%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,799 in reported general payments places this provider in the 70th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$146,748
Medicare patients
259
Services billed
2,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa133$251,046
GocovriAmantadine Hcl38$124,219
Droxidopa37$19,155
Entacapone93$15,490
Rasagiline Mesylate43$14,932
Carbidopa-LevodopaCarbidopa/Levodopa254$8,309
Carbidopa-Levodopa ErCarbidopa/Levodopa199$5,739
Propranolol Hcl ErPropranolol Hcl76$4,648
AmantadineAmantadine Hcl70$4,059
Baclofen115$4,057
Atropine Sulfate24$1,747
Primidone58$1,564
Memantine Hcl44$1,308
Midodrine Hcl17$1,251
Pramipexole DihydrochloridePramipexole Di-Hcl44$964

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$496$251,046133 claims
MDD US Operations, LLCGocovri$92$124,21938 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,434 neurology providers in Florida.

Other neurology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →